The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study

Table 2 Causes of status epilepticus (SE) patients treated with intravenous phenytoin or intravenous sodium valproate as the first-line treatment

Causes	Phenytoin group N = 37	Sodium valproate N = 17	p value
Antiepileptic drug withdrawal	4 (10.81)	5 (29.41)	0.121
Sepsis	7 (18.92)	0	0.084
Uremia	0	1 (5.88)	0.315
Cardiac arrest	5 (13.51)	2 (11.76)	1.000
Alcohol withdrawal	1 (2.70)	0	1.000
CNS infection	9 (24.32)	3 (17.65)	0.584
Head injury	2 (5.41)	0	1.000
Metabolic causes	9 (24.32)	1 (5.88)	0.105
Others*	10 (27.03)	6 (35.29)	0.537

Note. Data presented as median (range) or number (percentage); *phenytoin group: hypoxic encephalopathy 3, CNS vasculitis 2, epidural hematoma 1, postcraniotomy 1, tuberculous encephalitis 1, venous thrombosis 1, ischemic stroke 1; sodium valproate group: postcraniotomy 2, saggital sinus thrombosis 1, subarachnoid hemorrhage 1, intracerebral hemorrhage 1, pregnancy with eclampsia.

ISSN: 1471-2377